Gunter Krause
Overview
Explore the profile of Gunter Krause including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
305
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassenruck F, Farina-Morillas M, Neumann L, Landini F, Blakemore S, Rabipour M, et al.
Commun Biol
. 2023 Jun;
6(1):603.
PMID: 37277510
Targeting the PI3K isoform p110δ against B cell malignancies is at the mainstay of PI3K inhibitor (PI3Ki) development. Therefore, we generated isogenic cell lines, which express wild type or mutant...
2.
Krause G, Hassenruck F, Hallek M
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32899476
Cytokines are soluble protein factors with importance in intercellular communication and, as such, play pivotal roles in the pathogenesis of B cell malignancies. Evidence from in vitro cultures permitted us...
3.
Krause G, Hassenruck F, Hallek M
Br J Pharmacol
. 2020 Jan;
177(9):2163-2165.
PMID: 31994176
No abstract available.
4.
Krause G, Hassenruck F, Hallek M
Drug Des Devel Ther
. 2018 Sep;
12:2577-2590.
PMID: 30174412
On the occasion of its recent approval for relapsed follicular lymphoma, we review the design and development of the pan-class I PI3K inhibitor copanlisib as a drug for the treatment...
5.
Hassenruck F, Knodgen E, Gockeritz E, Midda S, Vondey V, Neumann L, et al.
Biomed Res Int
. 2018 May;
2018:1023490.
PMID: 29750146
The antibody-dependent cell-mediated cytotoxicity (ADCC) of the anti-CD20 monoclonal antibodies (mAbs) rituximab and obinutuzumab against the cell line Raji and isolated CLL cells and its potential impairment by kinase inhibitors...
6.
Gockeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenruck F, Neumann L, et al.
Br J Haematol
. 2017 Jun;
178(6):949-953.
PMID: 28573668
To elucidate their mechanism of action, inhibitors of Bruton tyrosine kinase (BTK) and resistant BTK mutants were employed to dissect target-dependent cellular functions. BTK-C481S and -T474I, expressed in Ramos and...
7.
Krause G, Baki I, Kerwien S, Knodgen E, Neumann L, Gockeritz E, et al.
Br J Haematol
. 2015 Aug;
173(5):791-4.
PMID: 26271483
No abstract available.
8.
Gockeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, et al.
Int J Cancer
. 2015 Apr;
137(9):2234-42.
PMID: 25912635
Pharmacological inhibition of phosphatiylinositide-3-kinase (PI3K)-mediated signaling holds great promise for treating chronic lymphocytic leukemia (CLL). Therefore we assessed three structurally related PI3K inhibitors targeting the PI3K-δ isoform for their ability...
9.
Reinart N, Nguyen P, Boucas J, Rosen N, Kvasnicka H, Heukamp L, et al.
Blood
. 2012 Nov;
121(5):812-21.
PMID: 23118218
Unlabelled: Survival of chronic lymphocytic leukemia (CLL) cells depends on stimuli provided by a suitable microenvironment. The factors and mechanisms providing this growth support for CLL cells are not fully...
10.
Sitnikov N, Velder J, Abodo L, Cuvelier N, Neudorfl J, Prokop A, et al.
Chemistry
. 2012 Aug;
18(38):12096-102.
PMID: 22927359
A series of novel pyrrolo-allocolchicine derivatives (containing a 1-methyl-1H-indol-5-yl moiety replacing ring C) was synthesized. The tetracyclic ring system was constructed by Suzuki-Miyaura cross-coupling of a 1-methylindole-5-boronate with an ortho-iodo-dihydrocinnamic...